Epidermal Growth Factor Receptor (EGFR), FISH
Epidermal growth factor receptor (EGFR) is a transmembrane protein on the surface of cells and is involved in cellular proliferation. Binding of certain ligands such as epidermal growth factor and transforming growth factor alpha stimulates tyrosine kinase, which leads to activation of signaling pathways associated with cell growth and survival. It is a member of the ErbB family of receptors. Mutations that lead to overexpression or over activity of EGFR have been demonstrated in many epithelial malignancies including colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC), and leads to tumor growth and progression. With the lower prevalence, overexpression of EGFR has been found to be associate with glioblastomas as well.
Activation leads to downstream signaling in the form of several signal transduction cascades. These include primarily the JNK, Akt, and MAPK pathways; activation of these leads to cellular proliferation via DNA synthesis. EGFR has become of prime interest for anti-cancer drug investigation. Some drugs, such as gefitinib and erlotinib, are directed specifically against the EGF receptor. Anti-EGFR drugs are either monoclonal antibodies that prevent growth factor binding or tyrosine kinase inhibitors that inhibit the signaling pathways. In order for a patient to be eligible to receive these drugs, it must be shown that the patient’s tumor possesses increased expression or activity, and this is the role of EGFR testing. Unfortunately, many patients develop resistance to a drug after a period of therapy, and as of 2010 there is no consensus on how to treat resistant tumors.
- To determine eligibility for cetuximab (Erbitux™’) treatment in patients with advanced metastatic colorectal cancer.
- To evaluate which lung cancer patients might benefit from anti-TKI therapy targeted specifically toward the epidermal growth factor receptor tyrosine kinase.
The number of EGFR gene copies are compared to an internal control and the ratio is reported with a pre-determined cutoff between not amplified or amplified.
EGFR is reported as not amplified or amplified.
- Normal: No EGFR amplification suggests that the patient is not suitable for cetuximab treatment.
- Abnormal: Amplified EGFR indicates good candidate for anti-EGFR receptor or anti-TKI treatment.
Normal: No EGFR amplification suggests that the patient is not suitable for cetuximab treatment.
Abnormal: Amplified EGFR indicates good candidate for therapy treatment.
Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH).
Formalin-fixed, paraffin-embedded tissue (FFPE) blocks or slides of surgical pathology biopsy/resection or cytopathology fine needle aspiration (FNA) specimens. Blocks should be transported at room temperature in a secure and sealed container, or unstained slides are both acceptable. Surgical pathology and cytopathology (FNA) specimens are acceptable.
Note: material for EGFR testing comes from patient tumor tissue processed by the formalin fixation paraffin embedded technique.
- Clin Cancer Res. 2009;15:5267-5273. [PMID: 19671843]
- Clin Cancer Res. 2006;12:4416s-4420s. [PMID: 16857820]
- PLosMed. 2005;2:e17. [PMID: 15696205]
- J Clin Oncol. 2005;23:5900-5909. [PMID: 16043828]
- Clin Cancer Res. 2007;13:2890-2896. [PMID: 17504988]
- J Clin Oncol. 2009;27:4247-4253. [PMID: 19667264]
- N Engl J Med. 2010;363:1693-1703. [PMID: 20979469]
- Clin Cancer Res. 2012;18:1472-1482. [PMID: 22235099]
- Eur J Cancer. 2001 Sep;37. [PMID: 11597399]
- NCCN Clinical Practice Guidelines in Oncology™. Non-small cell lung cancer. v 2. 2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed September 13, 2014.